Shares shifted as Helus Pharma (Nasdaq: HELP), formerly known as Cybin, priced a US$50 million underwritten public offering just hours before its lead depression drug trial hit a critical enrollment milestone. The stock jumped 9.1% to $5.29 in pre-market trading — a counterintuitive rally for a deal that dilutes existing shareholders, signaling the market sees the cash as more valuable than the shares it costs.
The Offering Dilutes Shareholders, but Removes a Bigger Fear. Helus priced 10,309,280 new shares at $4.85 apiece , a deal run by Cantor and Barclays as joint bookrunners . That price matched Monday's close exactly, meaning insiders negotiated zero discount to market — relatively rare for a biotech secondary. For a pre-revenue company that held $195.1 million in cash as of December 31 while posting a quarterly net loss of $42.7 million , the new capital pushes the runway further toward pivotal data readouts. Traders are essentially saying: we'd rather own a funded company than worry about a future fire-sale raise.
The Timing Is Not Accidental. Just yesterday, Helus disclosed that enrollment in its APPROACH Phase 3 trial — testing its lead depression therapy as an add-on treatment — has surpassed 86% . Topline results are expected in Q4 2026 . Raising capital now, while enrollment momentum is strong, lets management lock in funding before a binary data event that could swing the stock violently in either direction.
The Burn Rate Sets the Clock. Cash burn accelerated to $36.7 million per quarter in Q3, and the company also has a $100 million at-the-market facility it can tap incrementally. With $195 million already on hand plus today's $50 million gross raise, Helus has roughly six to seven quarters of runway at the current spend rate — enough to reach Phase 3 data and begin a regulatory filing if results are positive. Analysts have noted HELP trades near cash value, with an enterprise value of roughly $85 million against $195 million in cash — meaning the market assigns negative value to the pipeline itself.
What Shareholders Should Watch. HLP003 carries FDA Breakthrough Therapy Designation , a status that can accelerate review. Phase 2 data showed a 23-point improvement on a standard depression scale at 12 months after just two doses . If Phase 3 confirms that durability, the commercial story changes entirely. If it doesn't, today's raise simply delays the reckoning. Either way, the Q4 data readout is the only number that truly matters.